JYNT
The Joint Corp.
JYNT has the edge over NVO overall, supported by stronger valuation and stronger fundamentals.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
JYNT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Healthy |
JYNT's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
JYNT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $6.69 | — |
| Current | 33x | $6.69 | — |
| Cheap | 44x | $8.80 | +32% |
| Fair | 70x | $13.93 | +108% |
| Expensive | 110x | $22.06 | +230% |
Historical ranges are pointers, not guarantees.
JYNT's PE is in its cheap range at 33x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over JYNT in the historical PE scenario, which offers more potential upside but is not a forecast.
JYNT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect JYNT's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
JYNT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.33 | +63% |
| Q3 2026 | $0.20 | +54% |
| Q2 2026 | $0.27 | +$0.41 |
| Q1 2026 | $0.23 | +$0.62 |
| Q4 2025 | $0.20 | +$0.59 |
| Q3 2025 | $0.13 | +$1.26 |
| Q2 2025 | -$0.14 | +$0.83 |
| Q1 2025 | -$0.39 | +$0.36 |
| Q4 2024 | -$0.39 | +$0.26 |
JYNT's earnings per share have fallen from their peak: $0.20 over the past year, against $1.19 in late 2021.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
JYNT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $13.6M | +1.3% |
| Q2 2026 | $15.2M | +14% |
| Q1 2026 | $14.8M | +13% |
| Q4 2025 | $15.2M | +3.1% |
| Q3 2025 | $13.4M | -56% |
| Q2 2025 | $13.3M | -56% |
| Q1 2025 | $13.1M | -56% |
| Q4 2024 | $14.7M | -52% |
JYNT's revenue has grown year over year for four quarters in a row: $14M last quarter, up 1.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.8% | +8.6 points |
| Q2 2026 | -2.4% | +6.2 points |
| Q1 2026 | 5.9% | +11 points |
| Q4 2025 | 4.9% | -0.6 points |
| Q3 2025 | 1.2% | +12 points |
| Q2 2025 | -8.6% | +3 points |
| Q1 2025 | -5.2% | -8.9 points |
| Q4 2024 | 5.5% | +6 points |
JYNT's operating margin was 9.8% last quarter, up 8.6 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over JYNT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over JYNT on profitability, with a higher operating margin.
JYNT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$508.6K | -135% |
| Q2 2026 | $1.9M | +432% |
| Q1 2026 | -$1.7M | +$2.3M |
| Q4 2025 | $2.5M | -34% |
| Q3 2025 | $1.5M | -55% |
| Q2 2025 | $363.6K | +$1.6M |
| Q1 2025 | -$4M | -267% |
| Q4 2024 | $3.8M | +73% |
JYNT usually generates cash, though not every quarter: the latest was −$508,635, but it generated $2M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over JYNT on cash flow, with more consistent year-over-year improvement.
JYNT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -215K shares |
| 1 year | -8.9% | -1.4M shares |
| 3 years | -6.6% | -984K shares |
| 5 years | -6.3% | -938K shares |
| Available history | -3% | -436K shares |
JYNT has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.8M |
| Q2 2026 | $676,810 |
| Q1 2026 | $1.1M |
| Q4 2025 | $9M |
| Q3 2025 | $2.3M |
| Q2 2025 | — |
| Q1 2025 | $8,440 |
| Q4 2024 | — |
JYNT spent $15M buying back its own shares over the past year, about six times what it spent the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
JYNT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.5x | Net Cash |
| Q2 2026 | -7.1x | Net Cash |
| Q1 2026 | -8.9x | Net Cash |
| Q4 2025 | -31.2x | Net Cash |
| Q3 2025 | -39.9x | Net Cash |
| Q3 2024 | -180.9x | Net Cash |
| Q2 2024 | -5.0x | Net Cash |
| Q1 2024 | -2.5x | Net Cash |
JYNT has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
JYNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.4 | Neutral |
| Stochastic | 9.3 | Oversold |
JYNT's weekly RSI is 32 (neutral) and its Stochastic is 9 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
JYNT PE vs Healthcare Sector
| Metric | JYNT | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 26x | 29% above |
| PE % | 5 | 29 | 24 pts below |
JYNT is trading at 33x earnings, a 29% premium to the Healthcare sector's median of 26x.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over JYNT on valuation relative to its sector.
JYNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.17 | 6.7% below |
| 20 week MA | $7.96 | 16% below |
| 50 week MA | $8.54 | 22% below |
| 100 week MA | $9.49 | 30% below |
| 200 week MA | $10.9 | 39% below |
JYNT is in a downtrend: it's below all five of its weekly moving averages, and 39% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over JYNT on trend strength, trading above more of its moving averages.
JYNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.3 | $25.5 | +57% |
| 2021 | $25.5 | $64.7 | +153% |
| 2022 | $64.7 | $15.1 | -77% |
| 2023 | $15.1 | $9.61 | -36% |
| 2024 | $9.61 | $9.90 | +3% |
| 2025 | $9.90 | $8.76 | -12% |
| 2026 YTD | $8.76 | $6.69 | -24% |
JYNT's yearly returns have swung widely, from +153% in 2021 to −77% in 2022. It's down 24% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over JYNT on returns for 2026, with the stronger performance.